Adverse Events and Oncotargeted Kinase Inhibitors - Image 1

£133.29

Academic Press Adverse Events and Oncotargeted Kinase Inhibitors

Name: Adverse Events and Oncotargeted Kinase Inhibitors
Brand: Academic Press
Price: 133.29 GBP
Availability: InStock

Pharmacy - Dispensing

Price History & Forecast

Last 30 days • 30 data points (No recent data available)

Historical

Generating forecast...

Price Distribution

Price distribution over 30 days • 1 price levels

Days at Price

Price Analysis

Most common price: £133 (30 days, 100.0%)

Price range: £133 - £133

Price levels: 1 different prices over 30 days

Description

Adverse Events and Oncotargeted Kinase Inhibitors gathers and evaluates data on adverse events associated with tyrosine kinase inhibitors (TKIs), a powerful anti-tumor drug class that has recently been introduced for human therapy. This book compiles a comprehensive safety profile of each TKI from experiences in official therapeutic indications, also exploring off-label exploratory investigations and postmarketing pharmaceutical surveillance databases. A brief history of each drug’s development and submission is provided, along with a more detailed analysis of the mechanism(s) of action involved in therapeutic activity or related to the insurgence of specific adverse events. Early chapters focus on general characteristics of TKIs, typology, and classification of adverse events, while the final chapters analyze TKIs as AE inducers and classes of AEs by system or organ involvement. This comprehensive resource compiles and critically reviews all of the relevant safety data for this class of drugs, with the goal of improving the understanding of pathogenesis and facilitating the prevention, monitoring, and management of these adverse events. Offers a unique and comprehensive publication on the adverse events associated with a new and fast-growing class of medicines Provides a systematic analysis of adverse events aimed at better prevention through understanding and offering insights for the development of safer drugs Uses practical guidelines to establish a leading reference on this class of drugs for educators, researchers, drug developers, clinicians, safety professionals, and more

Product Specifications

Brand: Academic Press
Format: hardcover
ASIN: 0128094001
Category: Books > Subjects > Health, Family & Lifestyle > Medical & Healthcare Practitioners > Allied Health Professions > Pharmacy - Dispensing
Domain: Amazon UK
Release Date: 12 May 2017
Listed Since: 30 September 2016

Barcode

No barcode data available

Academic Press Adverse Events and Oncotargeted Kinase Inhibitors

Price History & Forecast

Price Distribution

Price Analysis

Description

Product Specifications

Barcode

Similar Products You Might Like

Adverse Events with Biomedicines: Prevention Through Understanding

Antitargets and Drug Safety (Methods & Principles in Medicinal Chemistry)

Cardiovascular Toxicity and Therapeutic Modalities Targeting Cardio-oncology: From Basic Research to Advanced Study

Protein Tyrosine Kinases: From Inhibitors to Useful Drugs (Cancer Drug Discovery and Development)

Academic Press Protein Kinase Inhibitors: Discovery to Therapeutics

Phase I Oncology Drug Development

Translational ADMET for Drug Therapy: Principles, Methods, and Pharmaceutical Applications

Chemistry and Pharmacology of Anticancer Drugs

CRC Press - Chemistry and Pharmacology of Anticancer Drugs

Protein Tyrosine Kinases: From Inhibitors to Useful Drugs (Cancer Drug Discovery and Development)

Inhibitors of Cyclin-dependent Kinases as Anti-tumor Agents: 3 (Enzyme Inhibitors Series)

Pharmacokinetics in Drug Development: Problems and Challenges in Oncology, Volume 4

Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy (Volume 4)

Molecules Engineered Against Oncogenic Proteins and Cancer: Discovery, Design, and Development

Pharmacoepidemiology and Pharmacovigilance: Synergistic Tools to Better Investigate Drug Safety

Clinical Evaluation of Antitumor Therapy: 46 (Developments in Oncology, 46)

Next Generation Kinase Inhibitors: Moving Beyond the ATP Binding/Catalytic Sites

Oligonucleotide-Based Drugs and Therapeutics: Preclinical and Clinical Considerations for Development

Cardiotoxicity of Chemotherapeutic Agents (Cancer Etiology, Diagnosis and Treatments: Cardiology Research and Clinical Developments)

Drug Safety Evaluation (Pharmaceutical Development Series)

Kinase Inhibitor Drugs (Wiley Series in Drug Discovery and Development)

Stephens' Detection and Evaluation of Adverse Drug Reactions: Principles and Practice

Academic Press Pharmacokinetics and Toxicokinetic Considerations II

Principles and Practice of Pharmacovigilance and Drug Safety